Literature DB >> 35125702

IgA Monoclonal Gammopathy with Pseudohyperphosphatemia.

Priti Rani1, Tarun Kumar1, Sushil Kumar1, Ayan Banerjee1, Mala Mahto1,2.   

Abstract

Monoclonal gammopathies (MGs) reflect conditions in which abnormal amounts of immunoglobulins are produced by a clone that developed from a single pro-B germ cell. They range from asymptomatic, benign disorders such as monoclonal gammopathy of undetermined significance to malignant plasma cell and lymphoid disorders, including multiple myeloma and Waldenstorm macroglobulinemia. The identification of the particular subtype of immunoglobulin molecule is done by serum immunofixation by use of specific antisera directed against different subtypes of immunoglobulin classes. However depending upon the characteristic position taken up by migrating M band on protein electrophoresis due to its molecular weight and charge, serum protein electrophoresis can itself reveal the nature of the immunoglobulin without the need to do serum immunofixation. IgA mostly migrates to beta globulin region and may often be missed out for lack of a sharp, discrete M band in gamma globulin region. Systemic manifestations of MG can be attributed to the physicochemical properties of the monoclonal immunoglobulin, to its antibody activity or to other mechanisms. We describe a case of IgA MG with pseudohyperphosphatemia. © Association of Clinical Biochemists of India 2020.

Entities:  

Keywords:  IgA monoclonal gammopathy; Multiple myeloma; Pseudohyperphosphatemia

Year:  2020        PMID: 35125702      PMCID: PMC8799830          DOI: 10.1007/s12291-020-00911-8

Source DB:  PubMed          Journal:  Indian J Clin Biochem        ISSN: 0970-1915


  11 in total

Review 1.  Malignant hematopoietic cell lines: in vitro models for the study of multiple myeloma and plasma cell leukemia.

Authors:  H G Drexler; Y Matsuo
Journal:  Leuk Res       Date:  2000-08       Impact factor: 3.156

2.  Guidelines for clinical and laboratory evaluation patients with monoclonal gammopathies.

Authors:  D F Keren; R Alexanian; J A Goeken; P D Gorevic; R A Kyle; R H Tomar
Journal:  Arch Pathol Lab Med       Date:  1999-02       Impact factor: 5.534

Review 3.  Factitious biochemical measurements resulting from hematologic conditions.

Authors:  Bakul I Dalal; Malcolm L Brigden
Journal:  Am J Clin Pathol       Date:  2009-02       Impact factor: 2.493

4.  Multiple Myeloma: The Case of the Disappearing Band.

Authors:  Linda Mamone; Jessica Jones; Shiguang Liu; Yanhua Li; Barbara Goldsmith; Adil I Khan
Journal:  Lab Med       Date:  2017-12-22

5.  Spurious hyperphosphatemia in a case of multiple myeloma.

Authors:  Sutirtha Chakraborty; Susruta Sen; Debkishore Gupta; Sidhartha Sankar Ghosh; Prasad Sawant; Mandrita Das
Journal:  Indian J Clin Biochem       Date:  2013-08-08

6.  Pseudohyperphosphataemia in multiple myeloma.

Authors:  R C Hawkins
Journal:  Ann Clin Biochem       Date:  1991-05       Impact factor: 2.057

7.  Spurious hyperphosphataemia caused by an IgA paraprotein: a topic revisited.

Authors:  David Sinclair; Helen Smith; Pamela Woodhead
Journal:  Ann Clin Biochem       Date:  2004-03       Impact factor: 2.057

8.  Review of 1027 patients with newly diagnosed multiple myeloma.

Authors:  Robert A Kyle; Morie A Gertz; Thomas E Witzig; John A Lust; Martha Q Lacy; Angela Dispenzieri; Rafael Fonseca; S Vincent Rajkumar; Janice R Offord; Dirk R Larson; Matthew E Plevak; Terry M Therneau; Philip R Greipp
Journal:  Mayo Clin Proc       Date:  2003-01       Impact factor: 7.616

9.  Pseudohyperphosphatemia in a patient with multiple myeloma.

Authors:  Yonggu Lee; Taiyon Koo; Joo-Hark Yi; Jung-Hye Choi; Sang-Woong Han; Ile-Kyu Park; Ho-Jung Kim
Journal:  Electrolyte Blood Press       Date:  2007-12-31

10.  Pseudohyperphosphatemia in a patient with relapsed multiple myeloma after bone marrow transplantation: A case report.

Authors:  Kittrawee Kritmetapak; Sophon Dumrongsukit; Jittirat Jinchai; Panibud Wongprommek
Journal:  Clin Case Rep       Date:  2019-06-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.